Bromocriptine formulations
The present application describes pharmaceutical formulations of bromocriptine mesylate and methods of manufacturing and using such formulations. The formulations are useful for improving glycemic control in the treatment of type 2 diabetes.
1. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv10 of less than 2 μm and a volume-based particle size distribution with a span of about 2 or lower; and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
2. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 1 .
3. The method of claim 2 , wherein the dosage form is administered in the morning within about two hours after waking.
4. A dosage form comprising: bromocriptine and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv10 of less than 2 μm and a volume-based particle size distribution with a span of about 2 or lower; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
5. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 4 .
6. The method of claim 5 , wherein the dosage form is administered in the morning within about two hours after waking.
7. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than 20 μm, a Dv50 of less than 10 μm and a Dv10 of less than 5 μm, and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
8. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 7 .
9. The method of claim 8 , wherein the dosage form is administered in the morning within about two hours after waking.
10. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than 20 μm, and a Dv50 of less than 10 μm, and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
11. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 10 .
12. The method of claim 11 , wherein the dosage form is administered in the morning within about two hours after waking.
13. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than 20 μm and a Dv10 of less than 5 μm, and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
14. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 13 .
15. The method of claim 14 , wherein the dosage form is administered in the morning within about two hours after waking.
16. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than 10 μm, and a Dv10 of less than 5 μm, and wherein the dosage form provides a dissolution profile, when tested in USP Apparatus Type 2 Paddle Method at 50 rpm in 500 mL of 0.1 N hydrochloric acid at about 37° C., wherein at least about 80% of the bromocriptine has been released at about 30 minutes.
17. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 16 .
18. The method of claim 17 , wherein the dosage form is administered in the morning within about two hours after waking.
19. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv90 of less than 20 μm and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
20. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 19 .
21. The method of claim 20 , wherein the dosage form is administered in the morning within about two hours after waking.
22. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv50 of less than 10 μm and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
23. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 22 .
24. The method of claim 23 , wherein the dosage form is administered in the morning within about two hours after waking.
25. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a Dv10 of less than 5 μm and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
26. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 25 .
27. The method of claim 26 , wherein the dosage form is administered in the morning within about two hours after waking.
28. A dosage form comprising: bromocriptine in micronized form and one or more excipients; wherein the dosage form provides for absorption of a substantial amount of bromocriptine through the gastric and/or intestinal mucosa when administered to a subject; wherein the bromocriptine has a volume-based particle size distribution with a span of less than 3; and wherein the dosage form exhibits a pharmacokinetic profile wherein the time to maximum plasma concentration (T max ) of bromocriptine is between about 30 and about 60 minutes following oral administration of the dosage form to the subject under fasting conditions or the T max of bromocriptine is between about 90 and about 120 minutes following oral administration of the dosage form to the subject under high fat fed conditions.
29. A method of treatment for improving glycemic control in a type 2 diabetes patient comprising orally administering to the patient a dosage form according to claim 28 .
30. The method of claim 29 , wherein the dosage form is administered in the morning within about two hours after waking.